Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,544 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Women-Only Clear all
Terminated Phase 3 Interventional Results available

Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

NCT05264506
View directory record Official record
Conditions
Contraception
Interventions
NOMAC-E2 COC
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
14 Years to 35 Years · Female only
Enrollment
3,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 22, 2026, 10:17 PM EDT
Not listed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

NCT00012311
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CMF regimen, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, fluorouracil, ifosfamide, methotrexate, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 59 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

NCT02817464
View directory record Official record
Conditions
Pregnancy, Contraception
Interventions
TV-46046 - 400 mg/mL, TV-46046 - 200 mg/mL
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 2Phase 3 Interventional

Female Orgasmic Disorder (FOD) and Wellbutrin XL

NCT00248209
View directory record Official record
Conditions
Orgasmic Disorder
Interventions
Wellbutrin XL
Drug
Lead sponsor
Segraves, R., T., M.D., Ph.D.
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 22, 2026, 10:17 PM EDT
Active, not recruiting No phase listed Observational

An Observational Study of Individuals With Isolated Dystonia

NCT07111663
View directory record Official record
Conditions
Isolated/Primary Dystonia That Affects More Than One Region of the Body
Interventions
Not listed
Lead sponsor
Vima Therapeutics
Industry
Eligibility
12 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
29
States / cities
Scottsdale, Arizona • Sun City, Arizona • Aliso Viejo, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

NCT01254292
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 29 Years · Female only
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
24
States / cities
Tucson, Arizona • La Mesa, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Not applicable Interventional

Ultrasound First Clinical Decision Support for Suspected Nephrolithiasis

NCT03461536
View directory record Official record
Conditions
Nephrolithiasis
Interventions
Ultrasound-first Clinical Decision Support tool
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 22, 2026, 10:17 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Pilot Study: Mobile Phone Based Physical Activity in Sedentary Men and Women

NCT01435564
View directory record Official record
Conditions
Sedentary Lifestyle, Physical Activity
Interventions
Mobile phone, pedometer only
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 69 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 22, 2026, 10:17 PM EDT
Completed No phase listed Observational

Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening

NCT02310698
View directory record Official record
Conditions
Breast Cancer Screening
Interventions
contrast enhanced digital mammography (CEDM), whole breast screening ultrasound (WBUS)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Not applicable Interventional

TACAD Program for Asian American Family Caregivers of Persons Living With Alzheimer's Disease

NCT05615233
View directory record Official record
Conditions
Alzheimer Disease
Interventions
TACAD, Alzheimer's Association website
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 2 Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

NCT03113825
View directory record Official record
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

NCT02080468
View directory record Official record
Conditions
Healthy
Interventions
lomitapide, EE/norgestimate
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder

NCT02570282
View directory record Official record
Conditions
Sexual Arousal Disorder
Interventions
Placebo, SST-6007
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Early Detection of Breast Cancer Using Tomosynthesis Imaging

NCT00637598
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Mammography and tomosynthesis imaging
Radiation
Lead sponsor
Duke University
Other
Eligibility
Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

NCT03973047
View directory record Official record
Conditions
Nausea
Interventions
Bremelanotide, Zofran, Placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buoy Electrolyte Study on Hydration Status of Active Men and Women

NCT05768789
View directory record Official record
Conditions
Dehydration, Electrolyte Imbalance, Electrolyte Depletion, Fluid and Electrolyte Imbalance
Interventions
Buoy Electrolyte, Water only, Nuun Electrolyte
Dietary Supplement · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 22, 2026, 10:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Responses to Physical Activity Messages Among Midlife Adults

NCT04711512
View directory record Official record
Conditions
Exercise, Sedentary Behavior, Motivation
Interventions
Encouragement/Support, Social Comparison
Behavioral
Lead sponsor
Rowan University
Other
Eligibility
40 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glassboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 22, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional Results available

(mo)BETTA Trial in Transwomen for Optimization of ART

NCT03348163
View directory record Official record
Conditions
HIV Infections
Interventions
B/FTC/TAF, Current ART
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake

NCT02517593
View directory record Official record
Conditions
Breast Cancer
Interventions
Polygenic Risk Score
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 22, 2026, 10:17 PM EDT
Active, not recruiting Phase 2 Interventional

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

NCT05607004
View directory record Official record
Conditions
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
(Z)-endoxifen, goserelin
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922

NCT02661893
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Rifampin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 10:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

NCT00556400
View directory record Official record
Conditions
Aplastic Anemia, Menorrhagia, Amenorrhea
Interventions
Lo-Ovral Oral Contraceptive Pills, Placebo - sugar pill
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 55 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation

NCT02353806
View directory record Official record
Conditions
Chronic Hypertension in Pregnancy
Interventions
Amlodipine besylate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 22, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

NCT02300363
View directory record Official record
Conditions
Healthy
Interventions
Treatment A (rosuvastatin), Treatment B (LX4211), Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 22, 2026, 10:17 PM EDT